Zhejiang Shapuaisi Pharmaceutical Co Ltd. Stock Analysis 603168.SS

Zhejiang Shapuaisi Pharmaceutical Co., Ltd. engages in the production, research, development, and sale of chemical preparations and proprietary medicines. The company is headquartered in Jiaxing, Zhejiang and currently employs 1,142 full-time employees. The company went IPO on 2014-07-02. The firm primarily operates its businesses through two segments. The Commodity Sales segment mainly covers the treatment fields of ophthalmic drugs (anti-cataract drugs), and antimicrobial drugs (cephalosporins, quinolones), and main products include benzalkonium chloride eye drops, cefixime products and other products. The Diagnosis and Treatment Service segment mainly provides ophthalmic specialty medical services, and provides medical services through the gynecology, obstetrics, pediatrics and other medical and technical departments of obstetrics and gynecology hospitals. The firm mainly conducts its businesses in the domestic market.